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Yuding Wang1, Michael R Lang1, Christopher L Pin2 and Jonathan I Izawa1,3,4*Abstract
Purpose: To identify the origin of synchronous and metachronous urothelial carcinoma (UC) of the bladder and
upper urinary tract to get a better understanding of the basic mechanism behind the multifocality of UC, which
may provide a sound bases for the future development of new strategies for detection, prevention and therapy.
Methods: Six patients with UC of the bladder and synchronous or metachronous UC of the upper urinary tract
were studied. Genetic analysis involving the study of loss of heterozygosity (LOH) has been evaluated on their
tumours using well characterised and new markers of UC (D9S171, D9S177, D9S303 and TP53).
Results: Five of the six patients demonstrated informative results. Four of five (80%) of patients had synchronous or
metacharonous UC tumour and showed patterns of LOH consistent with tumorigenesis from monoclonal tumour
origin. One of five (20%) patients exhibited a LOH consistent with oligoclonal tumorigenesis.
Conclusion: These findings suggest that both the monoclonal and field cancerization theory of tumorigenesis may
play a role in tumors of the urothelial tract. However, more data is needed.
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Urothelial carcinoma (UC) of the bladder is the fifth most
common solid cancer in the industrialized world (Cordon-
Cardo 2008). In Canada, approximately 7000 Canadians
will be diagnosed with this disease (Canadian Cancer Soci-
ety Cancer Statistics 2012). Approximately 30% of pa-
tients will present with de novo invasive UC and 30-40%
of these patients will eventual succumb to metastatic dis-
ease (Cordon-Cardo 2008; Canadian Cancer Society Cancer
Statistics 2012). UC of the upper urinary tract (UUT) is
much less common, accounting for 5% of all urothelial
malignancies (Kauffman & Raman 2008). Even though UC
of the bladder and of the UUT originate from the same
contiguous epithelial lining, primary UC of the bladder* Correspondence: jonathan.izawa@lhsc.on.ca
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genetic, molecular and clinical differences (Kauffman &
Raman 2008). Nevertheless, UC of the bladder and of
the UUT are intricately related, as these malignancies are
often complicated with synchronous or metachronous
malignancies of the bladder (Kang et al. 2003). Approxi-
mately 20-50% of patients with UC of the UUT will have
tumour involvement in the bladder (Kauffman & Raman
2008; Kang et al. 2003). Similarly, a much smaller percent-
age of UC of the bladder patients go on to develop UC
of the UUT (Habuchi 2005). A question of significance
surrounds whether these synchronous or metachronous
malignancies involving the bladder and subsequently
the UUT (or vice versa) represent a clonal or oligoclonal
process. The answer to this question may have signifi-
cant ramifications clinically on specific cancer surveil-
lance of the bladder and UUT, intensity of surveillance
and therapeutic modalities, such as prophylactic immuno-
therapy or chemotherapy delivered for individual patients
(Duggan et al. 2004).n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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that address the issue of intravesical chemotherapy to
decrease the recurrence rate of UC of the bladder follow-
ing a nephroureterectomy for UUT UC (Ito et al. 2013;
O’Brien et al. 2011). These studies both observed that
a single dose of intravesical chemotherapy following
nephroureterectomy for UUT UC appeared to decease
the risk of UC recurrence in the bladder. Knowing the
clonality of UUT UC vs. metachronous UC of the bladder,
for example, may allow for the prediction of the response
to therapies, such as the intravesical chemotherapies
described in these prospective trials (Ito et al. 2013;
O’Brien et al. 2011). It may then be possible to more
accurately determine which patients would benefit from
these types of therapies vs. those in which these therapies
are ineffective and can be withheld.
The clonal or oligoclonality of UC of the urothelial
tract has been a hotly debated question. It is known that
UC of urothelial tract commonly present as multifocal
tumours (Hafner et al. 2002). The clonal explanation is
known as the single transformed cell hypothesis, while
the oligoclonal explanation is known as the field defect
hypothesis (Hafner et al. 2002). In the single transformed
cell hypothesis, it is postulated that a single cell picks up
oncogenic ability and begins to proliferate and through
intraluminal seeding (and implantation) or intraepi-
thelial spread, causing multifocal tumour development
(Hafner et al. 2002). Therefore, all tumours in the single
transformed cell hypothesis share a common cell of ori-
gin, and thus common genetic alterations (O’Brien et al.
2011). Conversely, in the field defect hypothesis, it is
postulated that a “patch” of urothelium is exposed to
carcinogenic insult, and subsequently picks up oncogenic
potential, with each cell within the patch acquiring indi-
vidual genetic alterations (Höglund 2007). Individual cells
within this patch go on to develop tumours. In this model,
multifocal tumours develop from distinct cells within the
urothelium (Höglund 2007).
Significant work evaluating the clonality of tumours
within the urothelial tract have yielded conflicting results
in favour of both the clonal and oligoclonal origin of
synchronous and metachronous tumours (Hafner et al.
2002). Seminal work by Sidransky et al. evaluated the ori-
gin of multifocal UC of the bladder by using x-inactivation
and loss of heterozygosity (LOH) as a measure of
clonality (Sidransky et al. 1992). He showed that pre-
dominately multifocal tumours within the bladder show
identical x-inactivation profiles (a normally random process
in females) (Sidransky et al. 1992). Similarly, findings by
Habuchi et al., Miyo et al., Xu et al., and Chern et al.
looking at p53 oncogene heterogeneity of multifocal UC
of the bladder substantiated the clonal origin conclusion
demonstrated by Sidransky (Habuchi et al. 1993; Miyao
et al. 1993; Xu et al. 1996; Chern et al. 1996). More recentstudies using an array of molecular genetic techniques as
well as more specific loci for LOH studies have further
added evidence to the single cell hypothesis. However,
concurrent studies by Spruck et al., Hartmann et al.,
Takashi et al., and Hafner et al. have also shown evidence
for field defect theory using similar molecular genetic
techniques (LOH, and X-inactivation) (Stoehr et al.
2000; Hartmann et al. 2000; Takahashi et al. 2001;
Hafner et al. 2001). Interestingly, the tumours identified
showing oligoclonality were precursors or early stage
tumours suggesting that UC of the bladder might be a
multistep process (Takahashi et al. 2001; Hafner et al.
2001). Nevertheless, the predominate number of findings
to date, suggest that most UC of the bladder to be from
a single cell origin.
However, most of the clonality studies focused on syn-
chronous or metachronous tumours involving the blad-
der alone, only three studies have looked at synchronous
or metachronous tumours involving both the bladder
and UUT (Takahashi et al. 2001; Hafner et al. 2001;
Jones et al. 2005). Takahashi et al. analysed 34 tumours
from 15 patients with UUT UC and subsequent UC of
the bladder using LOH analysis on 21 microsatellite markers
across eight chromosomes (Takahashi et al. 2001). It was
found that 6 of 15 patients showed distinct microsatellite
alteration patterns. This was in contrast to recurrent
tumours within the bladder alone, evaluated in the same
study, which showed only 2 of 16 patients with distinct
microsatellite alteration patterns (Takahashi et al. 2001).
A similar study published in the same year by Hafner et al.
looked at 94 tumours from 19 patients with at least one
tumour both within the UUT and bladder using nine
markers (Hafner et al. 2001). Results showed that 5 of
19 patients showed at least two tumour clones with dif-
ferent genetic alterations. Interestingly, 4 of the 5 patients
had UC of the bladder before UC of the ureter (Hafner
et al. 2001). It is observed that UC of the UUT only occur
in 0.5-2% of bladder cancer, suggesting that the tumours
in these four patients were likely as arise independently
(due to field defect) as opposed to intraluminal seeding
(Habuchi 2005). Unfortunately, four of the five patients
were male, while the last patient had non-informative
loci for x-inactivation analysis. The last study by Jones
et al. examined 58 tumours from 21 patients with 9 of
the 21 patients having concurrent UUT UC and bladder
UC (Jones et al. 2005). Five of nine patients showed differ-
ent allelic loss patterns. Confirmation using x-inactivation
analysis showed four of the five patients to exhibit random
pattern of x-inactivation consistent with oligoclonality.
These studies taken together suggest that oligoclonality
maybe more frequent in cases with both UC of the
bladder and UUT. This may be due to the fact that
there are biological and clinical differences between the
urothelium of the UUT and bladder (Kauffman & Raman
AB
Figure 1 Precise microdissection of bladder carcinoma. A) tumour
before microdissection and B) after microdissection.
Table 1 Summery of loci evaluated of pathologically
identified normal tissue of each patient case
Patient Microsatellite markers
D9S171 D9S177 D9S303 TP53
N1 - - - -
N2 - - - +
N3 - - - +
N4 + + - -
N5 - + - -
N6 - + + +
(+) signifies informative loci, (−) signifies non-informative loci, and (?) signifies
loci that could not yet be determined.
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inactivated carcinogens may only have an effect on the
UUT while exposure time to carcinogen may correlate
with its carcinogenic effect on the bladder urothelium
(Takahashi et al. 2001; Hafner et al. 2001). However, it
is also possible that the long distance between the
UUT and bladder may prevent the dominant growth
of one dominant clone, which may mask oligoclonality
(Hafner et al. 2002).
Animal studies using the murine (chimeric C3H/NeN-
BALK/c) model exposed to known carcinogen N-butyl-
N-(4-hydroxybutyl)nitrosamine has shown oligoclonal
tumour development in 30% of mice, suggesting that the
field defect means of tumorigenesis plays a significant role
in cancer of urothelial tract (Yamamoto et al. 1998).
The three studies to date represent a small sample
size. Furthermore, LOH by itself cannot confer clonality
and is only as accurate as markers used in its analysis.
New, more specific, loci identified to more closely match
early events of tumorigenesis may offer better specificity
compared to late markers of tumorigenesis, which are
biased to genomic instability inherent in late cancer patho-
genesis (Habuchi 2005; Hafner et al. 2002). With the use
of new more specific markers coupled with previously
established markers, we hope to offer new insight into
nature of synchronous or metachronous UC of the blad-
der and UUT.
We hypothesized that synchronous and metachronous
UC of the bladder and UUT will exhibit both oligoclonal
and clonal characteristics pointing to a hybrid model of
urothelial tumorigenesis that may be important to tumour
development throughout the urothelial tract.
Methods
Patients
6 patients (5 male/ 1 female) with UC of the UUT and
synchronous or metachronous bladder UC that under-
went surgical excision of their tumours were identified.
These patients underwent nephroureterectomy for their
UUT tumour(s) and transurethral resection of their blad-
der tumour(s). All tumours excised were high grade UC.
The patients were not treated with any radiotherapy or
chemotherapy prior to their surgical resection. Patients
had not received any intravesical chemotherapy or im-
munotherapy for the bladder tumours. Tissue sample
and microdissection: Formalin fixed paraffin embedded
archival tissue was cut to 5um sections, and stained with
haematoxylin and eosin for microscopic evaluation. Patho-
logical identification of tumours was done with guidance
of pathologist. Laser assisted microdissection of neoplastic
tissue was performed using the PixCell II Laser-Capture
MicrodissectionW apparatus (Figure 1). The exact tumour
length of the entire tumour could not be determined
accurately using the archival tissue. However, no tumourswere so large and extensive to grow into the bladder and
cause direct invasion of the bladder.DNA purification
DNA was isolated using a phenol/chloroform system and
quantified using DNA MicrodropW quantification system.
Table 2 Loss of heterozygosity and x-inactivation analysis
of synchronous and metachronous urothelial carcinomas
Patient Samples Allelic loss of heterozygosity markers
D9S171 D9S177 D9S303 TP53
1. Normal NI NI NI NI
UTT +/− +/+ +/+ NI
Bladder +/− +/+ +/+ NI
2. Normal NI NI NI +/+
UTT −/− NI −/− −/−
Bladder +/− NI −/− −/−
3. Normal NI NI NI +/+
UTT NI NI NI −/−
Bladder NI NI NI −/−
4. Normal +/+ +/+ NI NI
UTT +/− +/+ NI NI
Bladder +/− +/− NI NI
5. Normal NI NI NI NI
UTT NI NI NI NI
Bladder NI NI NI NI
6. Normal NI +/+ +/+ +/+
UTT +/− +/+ +/− +/−
Bladder +/− +/+ +/− −/−
(+/+) heterozygosity, (+/−) LOH of the lower band, (−/+) LOH of the upper
band, (−/−) complete loss of allele, (NI) non-informative results.
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used to amplify genomic DNA at four specific loci on two
different chromosomes: 9p21 (D9S171), 9q32 (D9S177),
9q22 (D9S303) and 17p13 (TP53). D9S171 is associated
with tumour suppressor gene p16, a well characterized
marker of early bladder tumorigenesis (Jones et al. 2005;
OMIM D9S171- accessed 2010, updated 2010). D9S177 is
associated with putative tumour suppressor gene shown
in study, when altered, to be associated with one of the
earliest markers of the development of UC of the bladder
(OMIM D9S177- accessed 2010, updated 2009; Eguchi
et al. 2010). D9S303 is associated with the PTCH proto-
oncogene (Cordon-Cardo 2008; OMIM D9S303- accessed+’ve     -‘ve Ureter Bladder Nor     
D9S177
Figure 2 Representative results of LOH analysis (patient 4) showing o2010, updated 2010). TP53 was also studied because it
is a common marker of bladder tumour present in over
50% of bladder tumours (Cordon-Cardo 2008). Analysis
of LOH: PCR amplification of dissected tumour and
normal from the same sample was visualized using an
acrylamide gel system (20%). A heterozygous normal was
considered to be informative. Two independent raters
evaluated the sample to assess for heterozygosity. Tu-
mours of the UTT and bladder with the same pattern of
LOH was considered from a clonal origin while those
with different patterns of LOH was considered oligoclonal.
Results
The heterozygosity of each loci (D9S171, D9S177, D9S303
and TP53) was examined in 6 patients. Of the six patients,
five patients showed informative results (83%) in one of
the four loci studied. However, no patient showed inform-
ative results through all four loci (Table 1).
The loss of alleles as part of the tumorigenesis is a fre-
quent event and occurred in six of seven informative loci
identified in the five patients with informative loci (Table 2).
Of the five patients with informative loci, only one patient
(patient 4) showed a LOH pattern (loci D9S177) consistent
with a divergent origin or oligoclonality (Figure 2) while
the other four patients showed LOH pattern consistent
with a monoclonal origin (Table 2).
Discussion
The current study provides molecular evidence for the
role of both oligoclonal and monoclonal theory of tumori-
genesis of synchronous and/or metachronous tumours
of the urothelial tract. Four of five patients (80%) with
informative loci showed a monoclonal pattern of LOH,
while only one of five patients (20%) showed an oligoclonal
pattern of LOH. Unfortunately, the patient with the oligo-
clonal pattern of LOH was male, and a confirmatory
x-inactivation study could not be conducted. These find-
ings are consistent with results seen by Sidranksy et al.
(1992) Habuchi et al. (1993) Miyo et al. (1993) that show
tumours of the urothelial tract occur predominately
through a monoclonal process whereby a single cell is+’ve  Nor Bladder Ureter  -‘ve     
D9S171
nly informative loci D9S177 (left panel, and D9S171 (right panel).
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quently though further oncogenic insults or tumour evolu-
tion, proliferates and spreads either by intraluminal seeding
(and implantation) or intraepithelial spread to cause tu-
mours at a distant site. The observation that metastatic
tumours may undergo a phase of dominancy lasting from
months to years could account for latency of tumour
recurrence seen within the urothelial tract (Almog 2010).
However, one patient in our study group was observed
to show an LOH pattern consistent with an oligoclonal
pattern of tumorigenesis explained through the field
cancerization model. The two models of tumorigenesis
may not be mutually exclusive. Tumour chronological
experiments show that clonal evolution from a single cell
may result in pseudopolyclonality in the early stages of
tumorigenesis (low- grade tumours) while the overgrowth
of one clone in late stages tumorigenesis (high-grade
tumours) may result in pseudomonoclonality (Hafner et al.
2001). The 12 tumours studied so far from the 6 patients
in this experiment have all been diagnosed as high-
grade tumours. It is interesting to note that the patient
with an oligoclonal pattern was from a high- grade
tumour suggesting that the result seen is unlikely due to
pesudopolyclonality. Our data indicates that tumour
clonality of UUT UC may be a future clinical factor,
among others, to determine which patients may benefit
from therapies (Ito et al. 2013; O’Brien et al. 2011) to
prevent UC recurrences in the bladder.
A significant number of loci identified in this study
were non-informative. This was much higher than those
reported in similar studies by Jones et al. who used simi-
lar microsatellite markers. The heterozygosity of alleles
occurs in a random process and is dependent on adequate
sample size to mitigate chance variation. Only four loci
were evaluated in this study. Other potential loci identi-
fied in large genetic studies of urothelial cancers could
be added to strengthen the power of this study. These
potential loci include alleles located on 14q, 8p, 13q, and
11p showing signs of microsatellite instability present in
70%, 65%, 56%, and 54% of urothelial tumours respect-
ively (Hartmann et al. 1999). Another potential limita-
tion could be from the acrylamide visualization system
used in this study, which may not be sensitive enough to
detect minute differences in copy number variation. A
potential solution may be to send results for DNA sequen-
cing to find definitive changes between samples.
The results in this study are counter to those results
seen by Takashashi et al. (2001) Hafner et al. (2001) and
Jones et al. (2005) who have also evaluated the clonality
of metachronous and synchronous tumours of the UUT
and bladder. Our small sample size limited loci evalu-
ated, which may explain this difference. It is also interest-
ing to note that the current patient population studied
so far represent high-grade tumours, which are differentfrom the tumour populations (mix of high and low grade)
studied previously (Takahashi et al. 2001; Hafner et al.
2001; Jones et al. 2005).
In conclusion, the results show that most cases of UC
of the UUT that occur either synchronously or metach-
ronously to UC of the bladder seem to arise predom-
inately from a single cell origin that spreads either
through intraluminal seeding (and implantation) or intra-
epithelial spread. In one of case however, there was evi-
dence for tumour that may arise independently, consistent
with the field cancerization model. This suggest that
although the single cell theory of tumorigenesis may be
the predominate means of UC progression, the field
cancerization model may also play a small albeit signifi-
cant role, which must not be overlooked when consider-
ing appropriate treatments modalities, and when using
molecular diagnostic techniques to diagnosis and moni-
tor for disease recurrence.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YW and CP carried out the molecular genetic studies and drafted the
manuscript. JI provided the clinical data, study hypothesis and design and
drafted the manuscript. ML presented the data. All authors read and
approved the final manuscript.
Author details
1Department of Surgery, The Schulich School of Medicine and Dentistry,
London Health Sciences Centre-Victoria Hospital London, The University of
Western Ontario, London, ON, Canada. 2Divisions of Pediatrics, The Schulich
School of Medicine and Dentistry, London Health Sciences Centre-Victoria
Hospital London, The University of Western Ontario, London, ON, Canada.
3Divisions of Urology and Surgical Oncology, The Schulich School of
Medicine and Dentistry, London Health Sciences Centre-Victoria Hospital
London, The University of Western Ontario, London, ON, Canada. 4London
Health Sciences Centre-Victoria Hospital, 800 Commissioners Road East,
London, ON N6A 4G5, Canada.
Received: 9 December 2012 Accepted: 8 August 2013
Published: 28 August 2013
References
Almog N (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett
294(2):139–146
Canadian Cancer Society Cancer Statistics (2012) Accessed 2012. Pg10-11 http://
www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/
Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2012—English.pdf
Chern HD et al (1996) Clonal analysis of human recurrent superficial bladder
cancer by immunohistochemistry of P53 and retinoblastoma proteins. J Urol
156(5):1846–1849
Cordon-Cardo C (2008) Molecular alterations associated with bladder cancer
initiation and progression. Scand J Urol Nephrol Suppl 218:154–165
Duggan BJ et al (2004) Oligoclonality in bladder cancer: the implication for
molecular therapies. J Urol 171(1):419–425
Eguchi S et al (2010) The loss of 8p23.3 is a novel marker for predicting
progression and recurrence of bladder tumors without muscle invasion.
Cancer Genet Cytogenet 200(1):16–22
Habuchi T (2005) Origin of multifocal carcinomas of the bladder and upper
urinary tract: molecular analysis and clinical implications. Int J Urol
12(8):709–716
Habuchi T et al (1993) Metachronous multifocal development of urothelial
cancers by intraluminal seeding. Lancet 342(8879):1087–1088
Wang et al. SpringerPlus 2013, 2:412 Page 6 of 6
http://www.springerplus.com/content/2/1/412Hafner C et al (2001) Evidence for oligoclonality and tumor spread by
intraluminal seeding in multifocal urothelial carcinomas of the upper and
lower urinary tract. Oncogene 20(35):4910–4915
Hafner C et al (2002) Clonality of multifocal urothelial carcinomas: 10 years of
molecular genetic studies. Int J Cancer 101(1):1–6
Hartmann A et al (1999) Frequent genetic alterations in simple urothelial
hyperplasias of the bladder in patients with papillary urothelial carcinoma.
Am J Pathol 154(3):721–727
Hartmann A et al (2000) Clonality and genetic divergence in multifocal low-grade
superficial urothelial carcinoma as determined by chromosome 9 and p53
deletion analysis. Lab Invest 80(5):709–718
Höglund M (2007) On the origin of syn- and metachronous urothelial
carcinomas. Eur Urol 51(5):1185–1193, discussion 1193. Epub 2006 Nov 16
Ito A et al (2013) Prospective randomized phase II trial of a single early
intravesical instillation of pirarubicin (THP) in the prevention of bladder
recurrence after nephroureterectomy for upper urinary tract urothelial
carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol
31(11):1422–1427
Jones TD et al (2005) Molecular evidence supporting field effect in urothelial
carcinogenesis. Clin Cancer Res 11(18):6512–6519
Kang CH et al (2003) The development of bladder tumors and contralateral
upper urinary tract tumors after primary transitional cell carcinoma of the
upper urinary tract. Cancer 98(8):1620–1626
Kauffman EC, Raman JD (2008) Bladder cancer following upper tract urothelial
carcinoma. Expert Rev Anticancer Ther 8(1):75–85
Miyao N et al (1993) Role of chromosome 9 in human bladder cancer. Cancer Res
53(17):4066–4070
O’Brien T et al (2011) Prevention of bladder tumours after nephroureterectomy
for primary upper urinary tract urothelial carcinoma: a prospective,
multicentre, randomised clinical trial of a single postoperative intravesical
dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60(4):703–710
OMIM D9S171- accessed 2010, updated (2010) http://www.ncbi.nlm.nih.gov/
genome/sts/sts.cgi?uid=13653
OMIM D9S177- accessed 2010, updated (2009) http://www.ncbi.nlm.nih.gov/
genome/sts/sts.cgi?uid=26707
OMIM D9S303- accessed 2010, updated (2010) http://www.ncbi.nlm.nih.gov/
genome/sts/sts.cgi?uid=22557
Sidransky D et al (1992) Clonal origin bladder cancer. N Engl J Med 326(11):737–740
Stoehr R et al (2000) Oligoclonality of early lesions of the urothelium as determined
by microdissection-supported genetic analysis. Pathobiology 68(4–5):165–172
Takahashi T et al (2001) Distinct microsatellite alterations in upper urinary tract
tumors and subsequent bladder tumors. J Urol 165(2):672–677
Xu X et al (1996) Molecular screening of multifocal transitional cell carcinoma
of the bladder using p53 mutations as biomarkers. Clin Cancer Res
2(10):1795–1800
Yamamoto S et al (1998) Clonal analysis of urothelial carcinomas in
C3H/HeN<−−>BALB/c chimeric mice treated with N-butyl-N-(4-hydroxybutyl)
nitrosamine. Carcinogenesis 19(5):855–860
doi:10.1186/2193-1801-2-412
Cite this article as: Wang et al.: Comparison of the clonality of urothelial
carcinoma developing in the upper urinary tract and those developing
in the bladder. SpringerPlus 2013 2:412.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
